Plain-English translation of NCT07578584 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This is a Phase 1 clinical trial testing a new medication called , which is given as a weekly injection under the skin. The study will determine whether this medication is safe, well-tolerated, and effective in three groups: healthy people, people with overweight or obesity, and people with type 1 diabetes who also have overweight or obesity. Researchers will track how your body processes the medication and how it affects your weight and metabolism.
Current treatment options for weight management and type 1 diabetes are limited. This study explores whether this new treatment could offer an additional option for people struggling with weight, especially those living with type 1 diabetes.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will visit the research clinic multiple times over approximately 29 weeks for screening, treatment, and follow-up visits. During the study, you will receive either the new medication or a placebo (inactive injection) once per week as a shot under your skin. You will have blood tests, physical exams, and other routine health checks to monitor your safety and how your body responds to the treatment. The study team will carefully watch for any side effects and track changes in your weight and metabolic health.
AI-generated summary from trial data Β· Jun 16, 2026 Β· Not medical advice
Germany